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ong-Term Outcome
f Stem Cell Therapy for
cute Myocardial Infarction
ight Results, Wrong Reasons*
ames S. Forrester, MD, Raj R. Makkar, MD,
duardo Marba´n, MD, PHD
os Angeles, California
n this issue of the Journal, Yousef et al. (1) present the first
-year follow-up of intracoronary autologous bone marrow
ononuclear cell (BMC) infusion after acute myocardial
nfarction (AMI). An equal number of myocardial infarc-
See page 2262
ion (MI) patients who were offered the procedure but
eclined served as control subjects. An early significant
mprovement in ejection fraction (EF) and infarct size at 3
onths and 1 year was followed at 5 years by greater
xercise capacity and lower mortality (1 death vs. 7 deaths)
n the treated patients.
ssessing the Current Status
f Cardiac Stem Cell Therapy
he earliest clinical experience with intracoronary BMC
nfusion was nonrandomized, so this report is subject to the
ubstantial limitations of matched control study design,
hich include potential selection bias and retrospective
nalysis. However, the 1-year follow-up result of this study
s consistent with that of both randomized trials (2,3) and
eta-analyses (4). Thus, these data allow us the reasonable
onclusion that the procedure is safe and offers a small
ong-term improvement in cardiac function. The results also
uggest an additional unanticipated speculation: a small
unctional benefit might over time translate into more
triking long-term improvement in exercise tolerance and
urvival. This inference will need to be confirmed by
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles,
alifornia. Funding was provided by the National Heart, Lung and Blood Institute,
he Donald W. Reynolds Foundation, and the Lincy Foundation. Dr. Makkar is an
onsultant for Cordis and Medtronic. Dr. Marba´n is an equity holder and founder of
apricor, Inc.dditional data as it becomes available in the next few years.
f validated, we might need to question whether global
unction is a sufficiently sensitive measure of therapeutic
utcome, given the many physiologic compensatory mecha-
isms that stabilize resting function. In support of this idea, it
s worth noting that the EF benefit of prompt reperfusion is
mall (on average) but the clinical benefits are large.
The clinical outcome data, however, should not be used
o obscure a central issue in cell therapy of AMI: bone
arrow cells do not reproducibly generate new myocardium
5), and the observed benefit is most reasonably attributed to
aracrine effects. To achieve genuine cardiac regeneration, it
eems we might have to return to first principles to
nderstand the natural impediments to stem cell therapy
6). These barriers exist at the level of the pluripotent cell,
ts environmental regulators, and the tissue into which the
ell is delivered (7).
ells
lthough venerable and convenient, BMC might not be the
deal cell for cardiac regeneration. A large number of
lternative candidate cell types are being tested. Although
o consensus has yet emerged, a desirable cell type would be
utologous, capable of differentiating into all the adult cell
ypes in the heart, and highly resistant to malignant trans-
ormation. Arguably the 2 most promising types are induced
luripotent stem cells (iPS) derived from the patient’s own
issue and the patient’s own cardiac stem cells.
Induced pluripotent cells are derived from skin fibroblasts
y nuclear reprogramming, which involves insertion of
pecific transgenes into the fibroblast nucleus (8,9). The
esultant pluripotent cells, which very closely resemble
mbryonic stem cells, can then be directed into the specific
ell lines of different organs. “Guided cardiopoiesis” uses
ocktails of proteins that regulate embryonic cardiovascular
ifferentiation and diversification (10) to create cardiac cells
n vitro, including beating cardiomyocytes (11). Although
ot yet reported in cardiovascular application, iPS cells have
een used to markedly ameliorate Parkinson’s disease (12)
nd diabetes in animal models. The use of iPS in clinical
rials, however, will probably face significant regulatory
urdles, because in addition to their potential benefits, the
ethods for nuclear reprogramming carry the potential to
nduce euplastic transformation.
Closer to clinical application is the use of the patient’s
wn stem cells cultured from a cardiac biopsy. Two methods
re in current use. In 1 such method, enzymatically disso-
iated myocardial samples are enriched in cardiac stem cells
y cell sorting with xenogenic antibodies to a stem cell
ntigen before culture (13). This method purposely limits
he cell types selected and requires several months to yield
ufficient cells for therapeutic applications, even with source
issues as large as atrial appendages. An alternative method
s to culture the biopsy material first, allowing the sponta-
eous outgrowth of cells that can then be harvested to form
m
a
p
m
s
b
m
o
m
s
a
s
a
a
C
C
i
c
g
s
t
e
i
w
w
c
h
i
t
o
t
E
5
m
d
p
s
(
c
f
f
u
h
i
d
r
o
a
g
(
n

s
m
i
d
m
i
t
a
T
T
t
h
i
h
B
i
m
h
i
s
d
h
s
c
w
3
s
i
h
i
c
p
t
i
P
F
h
fi
b
w
w
h
b
t
B
a
n
t
g
e
2271JACC Vol. 53, No. 24, 2009 Forrester et al.
June 16, 2009:2270–2 Stem Cell Therapy for AMIulticellular structures called cardiospheres; cardiospheres
re then propagated in monolayer culture to yield the final
roduct (14). These cardiosphere-derived cells (CDC)
ight represent a broader spectrum of cardiac cell precur-
ors. Tens of millions of CDC can readily and reproducibly
e produced from tiny endomyocardial biopsies within a
atter of weeks. We have found that intracoronary infusion
f approximately 107 CDC in an autologous pig infarct
odel induces new myocardial tissue formation as well as a
ignificant decrease in relative infarct size (19.2% to 14.2%)
nd improved hemodynamic status compared with control
ubjects (15). A first-in-human trial of CDC in patients
fter MI has received Food and Drug Administration
pproval and is anticipated to begin shortly.
ell Environment
reation of a receptive cell environment is a second central
ssue in cardiac stem cell therapy. When labeled human
ardiomyocytes derived from embryonic stem cells are en-
rafted in uninjured rat hearts, 90% survive, whereas when the
ame human cells are injected into a peri-infarct area, they
ypically fail to engraft (16). This resistance to human stem cell
ngraftment can be overcome by a pro-survival cocktail, result-
ng in the appearance of segments of human myocardium
ithin the infarcted area and a 2.5-fold increase in regional
all thickening (17).
Insight into the mechanisms responsible for resistance to
ell engraftment after infarction comes from the wound-
ealing published data. Early in embryologic development,
njured tissue heals without scar formation. The transition
o adult-type scar formation coincides with the appearance
f the inflammatory process. Several recent studies suggest
hat the embryologic healing response is activated after MI.
mbryologic transcription factors are upregulated 2- to
-fold in infarcted rat myocardium, accompanied by as
uch as an 18-fold increase in their respective proteins at 14
ays (18) and 90-fold increase in the embryonic protein
eriostin. Progenitor cells are increased 4-fold in both the
ystemic circulation and tissue after infarction in humans
19,20). These data suggest a strategy aimed at tipping the
ell environment from that favoring adult scarring to one
avoring scarless healing.
Although the necessary and sufficient environmental factors
or optimal stem cell survival and proliferation are as yet
ndefined, some of these factors are prominent in embryologic
ealing after injury. Critical environmental modifiers seem to
nclude those that inhibit inflammation and apoptotic cell
eath and factors that promote cell growth. For instance, in
ats with hind limb paralysis, function was restored by embry-
nic stem cell-derived motor neurons only when anti-apoptotic
denosine derivatives were combined with neurotrophic
rowth factors, whereas the cells alone did not restore function
21). Indeed, in our own unpublished clinical trial of intracoro-
ary BMC infusion, 4 of 5 patients who responded with
15% increase in EF at 4-month follow-up received adeno- wine during the procedure. Conversely, in the porcine MI
odel, adding basic fibroblast growth factor to human CDC
ncreases donor-cell engraftment and enhances cardiomyocyte
ifferentiation in the transplanted hearts, resulting in improve-
ents in global ventricular function, regional wall motion, and
nfarct size (22,23). Taken together, the available data suggest
hat future cell therapy will include both pluripotent cells and
receptive cell environment.
iming and Method of Delivery
iming of stem cell therapy remains a conundrum, because
he early inflammatory response creates an environment
ostile to cell engraftment, whereas evolving fibrosis could
nhibit later therapy in the subacute and chronic phase of
ealing. In this report and the randomized clinical trials,
MC infusion typically was delayed for 5 to 7 days after
nfarction. This reasonable speculation that further delay
ight impede therapy, however, will have to be tested. We
ave found that delaying delivery of BMC in the porcine
nfarct model until 1 month after infarction resulted in
tabilization of cardiac function, with statistically significant
ifference from untreated control subjects (24), and others
ave reported similar outcomes with CDC (15). In chronic
table ischemic heart failure, a randomized trial of intra-
oronary BMC therapy showed EF increased by 2.9%,
hereas in those receiving no infusion, it fell by 1.2% at
-month follow-up. Thus, a small body of data suggests
imilar outcomes when cell therapy is delayed for longer
ntervals after infarction.
The present study and the others principally reviewed
ere rely on intracoronary delivery of cells into a recanalized
nfarct-related artery. Although this delivery method is
onvenient, there is no evidence to suggest that it is
referable to direct injection or to other approaches (e.g.,
opical cell-embedded scaffolds and image-controlled direct
ntramyocardial delivery) (25).
atient Population
inally, it is worth noting that the patient population used
ere and in most subsequent clinical BMC trials has been a
rst-infarct population with little ventricular dysfunction at
aseline, with a projected low mortality and morbidity even
ithout adjunctive biological therapy. Perhaps we cardiologists
ould be well-advised to take a page from the oncology
andbook and focus on critically ill patients who stand to
enefit dramatically, not incrementally, from these experimen-
al treatments.
Therefore, this publication of the first long-term results of
MC therapy in AMI serves as both a significant milestone
nd a pivot point in cardiovascular research. The therapy can
ow be considered safe and modestly efficacious. Conversely,
here is little evidence that it has achieved either the biologic
oal of regenerating new myocardium or the clinical goal of
fficacy sufficient to justify widespread use. As a consequence,
e must focus on the barriers to stem cell therapy at level of the
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Stem Cell Therapy for AMI June 16, 2009:2270–2ell, its environment, and the recipient tissue. Identification of
hese barriers provides both a stimulus to ongoing research and
justification for the hope that stem cell therapy will ultimately
chieve its much-anticipated potential. The race is on to find
etter cell types, create a receptive cell environment, optimize
elivery strategies, and identify the patient populations most
ikely to benefit from our ministrations.
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